This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Take the CME quiz:
 Vol. 16 No. 5, November 2006
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schiff, D.
Right arrow Articles by Barton, L. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Schiff, D.
Right arrow Articles by Barton, L. L.

AAP Grand Rounds 16:53 (2006)
© 2006 American Academy of Pediatrics

SENIOR MEMBERS & INFECTIOUS DISEASE

Nitazoxanide for Rotavirus Diarrhea—A Preliminary Trial

Source: Rossignol J-F, Abu-Zekry M, Hussein A, et al. Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial. Lancet. 2006;368:124–129; doi:10.1016/S0140-6736(06)68852-1[Medline]

The first 20% of the full text of this article appears below.

Rotavirus is the most common cause of severe, dehydrating gastroenteritis in young children worldwide and the estimated medical and societal costs of rotavirus disease in the US may reach $1 billion annually.1–3 Prevention of rotavirus disease by means of the new vaccines may significantly reduce the incidence and cost of rotavirus infection in those nations where their price is not prohibitive (see AAP Grand Rounds, April 2006;15:37–38[Free Full Text] 4). There . . . [Full Text of this Article]

Donald Schiff, MD, FAAP1 and Leslie L. Barton, MD, FAAP2
1 University of Colorado School of Medicine and The Children’s Hospital, Denver, CO
2 Pediatrics, University of Arizona, Tucson, AZ